TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29944553

Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM) in BCLP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM) in UCLP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (without NAM)
Number of subjects: 40
Study: 27021556

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 89

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 89
Study: 24832000

Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheters (IPCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 0
Study: 23775507

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 3314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3314
Study: 20367773

Group type: EXPERIMENTAL
Intervention: Tramadol HCl on-demand
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Daily paroxetine
Number of subjects: 35
Study: 19102862

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 1015
Study: 17148516

Group type: EXPERIMENTAL
Intervention: EMG biofeedback + exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 26
Study: 12643885

Group type: EXPERIMENTAL
Intervention: Admission ST depression > or =1mm
Number of subjects: 918

Group type: COMPARATOR
Intervention: No admission ST depression
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Persistent ST depression on discharge
Number of subjects: 918

Group type: COMPARATOR
Intervention: No ST depression on discharge
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Q-waves on discharge
Number of subjects: 918

Group type: COMPARATOR
Intervention: No Q-waves on discharge
Number of subjects: 918
Study: 11262895

Group type: EXPERIMENTAL
Intervention: Specific dietary regimen based on comprehensive diagnosis of metabolic disorders (group 1)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Non-specific dietary regimen after limited metabolic evaluation (group 2)
Number of subjects: 207
Study: 9322187

Group type: EXPERIMENTAL
Intervention: 500 micrograms of Cr as chromium picolinate, 2 times per day for 4 months
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 100 micrograms of Cr as chromium picolinate, 2 times per day for 4 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 8382969

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy (2 x 10(6) IU daily for a month, then every other day for 5 months)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 26
Study: 2873133

Group type: EXPERIMENTAL
Intervention: mesoridazine 400 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: thioridazine 800 mg/day
Number of subjects: 7

Group type: COMPARATOR
Intervention: chlorpromazine 1800 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: mesoridazine or thioridazine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: mesoridazine
Number of subjects: 7

Group type: COMPARATOR
Intervention: chlorpromazine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: thioridazine
Number of subjects: 7
Study: 29382036

Group type: EXPERIMENTAL
Intervention: BoNT/A injections into four glands
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BoNT/A injections into three glands
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BoNT/A injections into two glands
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BoNT/A injections (overall)
Number of subjects: 90
Study: 26606719

Group type: EXPERIMENTAL
Intervention: Case-Based Collaborative Learning (CBCL)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Problem-Based Learning (PBL)
Number of subjects: 64
Study: 24656867

Group type: EXPERIMENTAL
Intervention: Multimodal manual treatment approach including analyzing treadmill with feedback, isokinetic dynamometric muscle strengthening, and balance retraining on dynamic balance platform
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard care intervention for activities targeted to improve endurance, manual exercises of muscle strengthening, stretching exercises, gait, and balance exercises
Number of subjects: 27
Study: 22239291

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 2695

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 2695
Study: 20605769

Group type: EXPERIMENTAL
Intervention: Emotional Disclosure (Pennebaker Writing - PW)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Emotional Disclosure (King Writing - KW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study: 18443125

Group type: EXPERIMENTAL
Intervention: AMD3100 therapy for 10 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: AMD3100 therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline viruses from the X4 suppressor group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline viruses from the X4 nonsuppressor group
Number of subjects: 14
Study: 15994572

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12234230

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ESWT (1000 mJ/mm² total dose, given weekly for 3 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (6.0 mJ/mm² total dose)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ESWT
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 9811522

Group type: EXPERIMENTAL
Intervention: DTaP‐12.5 (12.5 microg PT and FHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP‐25 (25 microg PT and FHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine (DPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acellular vaccines (DTaP‐12.5 and DTaP‐25)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTP
Number of subjects: 0
Study: 7581587

Group type: EXPERIMENTAL
Intervention: Estrogen administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen administration with progestogen co-medication
Number of subjects: 0
Study: 3055672

Group type: EXPERIMENTAL
Intervention: 300 mg decaris weekly (150 mg for 2 successive days) for 15 months (group 3)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 300 mg decaris weekly (150 mg for 2 successive days) for 1 month (group I)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 300 mg decaris weekly (150 mg for 2 successive days) for 3 months (group 2)
Number of subjects: 92
Study: 30183531

Group type: EXPERIMENTAL
Intervention: Conditioning in artificial saliva (SAGF) for seven days at 37°C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conditioning in air for seven days at 37°C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dynamic and static three-point flexural testing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mini-flexural test (MFT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ISO flexural test (IFT)
Number of subjects: 30
Study: 28357715

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ortho‐Cyclen®
Number of subjects: 0
Study: 25987260

Group type: EXPERIMENTAL
Intervention: Serum bicarbonate level
Number of subjects: 2628

Group type: COMPARATOR
Intervention: Serum bicarbonate level (quartile with lowest bicarbonate ≤21 mEq/L)
Number of subjects: 2628
Study: 24282774

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 44

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 44
Study: 21296247

Group type: EXPERIMENTAL
Intervention: Passive smoke exposure (PSE)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Non-passive smoke exposure (non-PSE)
Number of subjects: 385
Study: 19167012

Group type: EXPERIMENTAL
Intervention: ST-segment resolution (STR) assessed immediately after primary PCI
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Maximum single-lead ST-segment elevation assessed immediately after primary PCI
Number of subjects: 28
Study: 16754727

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 19747

Group type: COMPARATOR
Intervention: Raloxifene (60 mg/d)
Number of subjects: 19747
Study: 15006009

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patches delivering 25 microg fentanyl/h (TTS‐fentanyl)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Paracetamol and codeine (P/C) 500 mg paracetamol and 30 mg codeine four times per day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS‐fentanyl)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Paracetamol and codeine (P/C)
Number of subjects: 26
Study: 11305684

Group type: EXPERIMENTAL
Intervention: N,N-dimethylglycine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9039618

Group type: EXPERIMENTAL
Intervention: Dynamic susceptibility contrast (DSC) MRI
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 32
Study: 8159516

Group type: EXPERIMENTAL
Intervention: Antimicrobial agents for otitis media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics for sinusitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cephalosporins or macrolides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 0
Study: 3884719

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.15 gm aspirin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.30 gm aspirin
Number of subjects: 30
Study: 29341103

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27470430

Group type: EXPERIMENTAL
Intervention: Tiotropium 10 µg delivered dose (Laboratorios Liconsa, Spain)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spiriva HandiHaler(®) (Boehringer Ingelheim Pharma GmbH & Co KG, Germany)
Number of subjects: 30
Study: 25826731

Group type: COMPARATOR
Intervention: CBT-MI alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBT-MI-SP (with support person)
Number of subjects: 0
Study: 22978405

Group type: EXPERIMENTAL
Intervention: VigRX Plus (VXP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: COMPARATOR
Intervention: VigRX Plus (VXP) and Placebo
Number of subjects: 78
Study: 20100135

Group type: EXPERIMENTAL
Intervention: 20 weeks of group exercise consisting of aerobic training and non-aerobic weight-lifting
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 48
Study: 19192440

Group type: EXPERIMENTAL
Intervention: Flunarizine (10-50 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Haloperidol (2.5-12.5 mg/day)
Number of subjects: 70
Study: 17956027

Group type: EXPERIMENTAL
Intervention: Spiggle foam pack
Number of subjects: 20

Group type: COMPARATOR
Intervention: Merocel foam pack
Number of subjects: 20
Study: 15088527

Group type: EXPERIMENTAL
Intervention: Karinat (2.5 mg beta-carotene, 5 mg alpha-tocopherol, 30 mg ascorbic acid, 150 mg garlic powder, one tablet twice a day for 6 months)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (one tablet twice a day for 6 months)
Number of subjects: 66
Study: 10698231

Group type: EXPERIMENTAL
Intervention: Enalapril (titrated oral dosage)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 9339507

Group type: EXPERIMENTAL
Intervention: WALLGRAFT Endoprosthesis
Number of subjects: 10

Group type: COMPARATOR
Intervention: WALLSTENT Endoprosthesis
Number of subjects: 10
Study: 8232766

Group type: EXPERIMENTAL
Intervention: RU 486 (10 mg/kg, p.o. at 8.00 h)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 15
Study: 3937403

Group type: EXPERIMENTAL
Intervention: Systemic antimicrobial prophylaxis with metronidazole and gentamicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metronidazole alone
Number of subjects: 0
Study: 30522822

Group type: EXPERIMENTAL
Intervention: Recovery programme for ICU survivors
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 181
Study: 28161697

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure reduction to a target of 120 mm Hg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard blood pressure management (not specified)
Number of subjects: 0
Study: 25850966

Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg, intravenous)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 66
Study: 22721608

Group type: EXPERIMENTAL
Intervention: Testosterone gel (150mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Estradiol gel (2mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 20623305

Group type: COMPARATOR
Intervention: Standard preventive rehabilitation (S)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Experimental preventive rehabilitation (E)
Number of subjects: 49
Study: 19167999

Group type: EXPERIMENTAL
Intervention: Antioxidants (specific types not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-ROMs test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antioxidant hierarchy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dosages of single antioxidants
Number of subjects: 0
Study: 16966852

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (group P)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (group NP)
Number of subjects: 50
Study: 14758376

Group type: EXPERIMENTAL
Intervention: Single dose of ciprofloxacin drops intraoperatively
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 5-day postoperative course of ciprofloxacin drops
Number of subjects: 150

Group type: COMPARATOR
Intervention: No antibiotic drops (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Single dose of ciprofloxacin drops (group 2)
Number of subjects: 150
Study: 11251353

Group type: EXPERIMENTAL
Intervention: Early invasive strategy with coronary angiography and revascularization procedures within 7 days after admission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalteparin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuation with dalteparin therapy after revascularization procedures
Number of subjects: 0
Study: 9489063

Group type: COMPARATOR
Intervention: Clomipramine (25‐150 mg daily)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dothiepin (75‐150 mg daily)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 101
Study: 7871037

Group type: EXPERIMENTAL
Intervention: Diazepam (FAST condition) - 20 mg single dose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diazepam (SLOW condition) - 6 doses of 4 mg administered at 30-min intervals
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diazepam (FAST condition)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diazepam (SLOW condition)
Number of subjects: 9
Study: 3544648

Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg, intramuscular injection)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Diclofenac (75 mg, intramuscular injection)
Number of subjects: 85
Study: 31166987

Group type: EXPERIMENTAL
Intervention: 15 μg/strain QVLP vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 μg/strain QVLP vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 μg/strain QVLP vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7.5 or 15 μg/strain QVLP vaccine with alum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29785686

Group type: EXPERIMENTAL
Intervention: Positive framing group (informed that dizziness is a sign that the drug had started to work)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neutral framing group (informed that dizziness is an unpleasant but well-known side effect)
Number of subjects: 80
Study: 26567961

Group type: EXPERIMENTAL
Intervention: Arms positioned in the superior direction (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Arms positioned in the ventral direction (Group B)
Number of subjects: 100
Study: 25363175

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg three times a day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Verapamil (10 mg every other week for up to 12 sessions)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination therapy (Pentoxifylline and Verapamil)
Number of subjects: 90
Study: 22610179

Group type: COMPARATOR
Intervention: Pressure support ventilation without a noninvasive mechanical ventilation algorithm (PSV-NIV-)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pressure support ventilation with a noninvasive mechanical ventilation algorithm (PSV-NIV+)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Neurally adjusted ventilatory assist without a noninvasive mechanical ventilation algorithm (NAVA-NIV-)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Neurally adjusted ventilatory assist with a noninvasive mechanical ventilation algorithm (NAVA-NIV+)
Number of subjects: 17
Study: 20609718

Group type: EXPERIMENTAL
Intervention: Harmonic FOCUS Shear (group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Electrocoagulation and clamp-and-tie technique (group B)
Number of subjects: 62
Study: 18562719

Group type: EXPERIMENTAL
Intervention: Systolic perfusion for ischemic segments
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Difference between systolic perfusion and diastolic perfusion in ischemic segments
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Diastolic perfusion
Number of subjects: 34
Study: 15987536

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily for 10 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no enoxaparin)
Number of subjects: 42
Study: 12494614

Group type: EXPERIMENTAL
Intervention: Model 6944 (small-surfaced, steroid-eluting electrode tip)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Model 6942 (conventional sized, steroid-eluting electrode tip)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Model 6944
Number of subjects: 34

Group type: COMPARATOR
Intervention: Model 6942
Number of subjects: 34
Study: 9475275

Group type: EXPERIMENTAL
Intervention: Irbesartan (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Angiotensin II infusion (2.5 ng/kg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Irbesartan (50 mg) pretreatment
Number of subjects: 10
Study: 7644839

Group type: EXPERIMENTAL
Intervention: BW0%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BW10%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Shrinking‐BW
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Expanding‐BW
Number of subjects: 120

Group type: COMPARATOR
Intervention: no‐KR retention condition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: KR retention condition
Number of subjects: 120
Study: 2562095

Group type: EXPERIMENTAL
Intervention: 15 ml of a local anesthetic solution containing 0.5% bupivacaine and 0.15 mEq of NaHCO3 (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 15 ml of a standard solution of 0.5% bupivacaine (Group II)
Number of subjects: 40
Study: 801352

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (LDH)
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Combined use of LDH and DHE
Number of subjects: 632

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Treated groups (LDH and DHE)
Number of subjects: 632
Study: 31379213

Group type: EXPERIMENTAL
Intervention: Eye shampoo with tea tree oil
Number of subjects: 62

Group type: COMPARATOR
Intervention: Artificial tears, topical steroids, and eye shampoos without tea tree oil (Control)
Number of subjects: 62
Study: 30534990

Group type: EXPERIMENTAL
Intervention: Inpatient portal
Number of subjects: 426

Group type: COMPARATOR
Intervention: Tablet-only
Number of subjects: 426

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 426
Study: 28678120

Group type: EXPERIMENTAL
Intervention: Debridement (CL‐Deb)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Observation (CL‐noDeb)
Number of subjects: 190
Study: 25616598

Group type: EXPERIMENTAL
Intervention: Intervention not explicitly mentioned; the focus is on the practice of testing for baseline differences in randomized controlled trials.
Number of subjects: 0
Study: 23220013

Group type: EXPERIMENTAL
Intervention: i.v. busulfan at a dose of 11.2 mg/kg/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: other doses of busulfan
Number of subjects: 80
Study: 21788312

Group type: EXPERIMENTAL
Intervention: 20% N(2)O
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 40% N(2)O
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 60% N(2)O
Number of subjects: 25
Study: 19920000

Group type: EXPERIMENTAL
Intervention: Daily school exercise lessons for 1 year
Number of subjects: 182

Group type: COMPARATOR
Intervention: Regular school sports twice weekly
Number of subjects: 182
Study: 16753973

Group type: EXPERIMENTAL
Intervention: Active NIV (8 cm H2O inspiratory and 4 cm H2O expiratory pressure)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham NIV (<1 cm H2O continuous positive airway pressure)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Active NIV and Sham NIV)
Number of subjects: 40
Study: 15300074

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) with hemodilution therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular hemodilution therapy only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (EECP and control) after 48 hours
Number of subjects: 20